Meldrum BS: GABAergic
mechanisms in the pathogenesis and treatment of epilepsy . Br J
Clin Pharmacol1989;27(Suppl
1):3S-11S.
2.
Gram L., Larsson OH,
Johnsen
A., Schousboe A.: Experimental
studies of the influence of vigabatrin on the GABA system . Br J
Clin Pharmacol1989;27(Suppl
1):13S-17S.
3.
Mumford JP: A profile of
vigabatrin. Br J Clin Pract1988
;42(Suppl
61):7-9.
Schechter PJ : Vigabatrin,
in Meldrum
RS, Porter RJ (eds): New Anticonvulsant
Drugs . London, John
Libbey, 1986, pp
265-275.
6.
Löscher W., Schmidt D.:
Which animal models should be used in the search for new antiepileptic
drugs? A proposal based on experimental and clinical considerations.
Epilepsy
Res1988;2:145-181.
7.
Grove J., Schechter PJ,
Tell
G., et al: Increased gamma-aminobutyric acid
(GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with
γ-vinyl GABA (4-amino-hex-5-enoic acid). Life
Sci1981;28:2431-2439.
8.
Schechter PJ , Hanke NFJ,
Grove
J.: Biochemical and clinical effects of
γ-vinyl GABA in patients with epilepsy.
Neurology1984;34:182-186.
9.
Mumford JP, Dam M.:
Meta-analysis of European placebo-controlled studies of vigabatrin in
drug resistant epilepsy. Br J Clin
Pharmacol1989
;27:101S-107S.
10.
Rimmer EM, Richens A.:
Double-blind study of gamma-vinyl GABA in patients with refractory
epilepsy . Lancet1984;1:
189-190.
11.
Gram L., Klosterkov P.,
Dam
M.: Gamma-vinyl GABA: A double-blind
placebo-controlled trial in partial epilepsy . Ann
Neurol1985;17:262-266.
12.
Loiseau P., Hardenberg JP,
Pestre
M., et al: Double-blind placebo-controlled
study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.
Epilepsia1986;27:115-120.
13.
Tartara A., Manni R.,
Galimberti
CA, et al: Vigabatrin in the treatment of
epilepsy. A double-blind placebo-controlled study.
Epilepsia1986;27:717-723.
14.
Remy C., Favel P.,
Tell
G., et al: Etude en double aveugle centre
placebo en permutations croisées du vigabatrin dans l'épilepsie de l'adulte résistant à
la thérapeutique. Boll Lega Ital
Epilepssia1986;54/55:241-243.
15.
Tassinari CA , Michelucci K.,
Hubrasetto
G., Salvi H.: Double-blind study
of vigabatrin in the treatment of drug-resistant epilepsy. Arch
Neurol1987
;86:907-910.
16.
Browne TR, Mattson RH,
Penry
JK, et al: Vigabatrin for refractory complex
partial seizures: Multicentre single blind study with long term
follow-up.
Neurology1987;37:184-189.
17.
Dam M.: Vigabatrin in
refractory epilepsy in adults and its application in children .
J Child
Neurol1991;6(Suppl):2S25-2S29.
18.
Browne TR, Mattson RH,
Penry
JK, et al: A multicentre study of vigabatrin
for drug-resistant epilepsy . Br J Clin
Pharmacol1989;27(Suppl
1):95S-100S.
19.
Butler WH: The
neuropathology of vigabatrin.
Epilepsia1989;30(Suppl
3):15-17.
20.
Graham D.: Neuropathology of
vigabatrin. Br J Clin
Pharmacol1989;27(Suppl
1):43S-45S.
21.
Gibson JP, Yarrington LT,
Loudy
DG, et al: Chronic toxicity studies with
vigabatrin, a GABA-transaminase inhibitor. Toxicol
Pathol1990;18:225-238.
22.
Butler WH, Ford GP,
Newberne
JW: A study of the effects of vigabatrin on
the central nervous system and retina of Sprague-Dawley and Lister-hooded
rats. Toxicol
Pathol1987;15:143-145.
23.
Pedersen B. , Hojgaard K.,
Dam
M.: Vigabatrin. No microvacuoles in a human
brain . Epilepsy
Res1987;1:74-76.
24.
Hammond EJ, Ballinger WE,
Wilder
BJ: Absence of neuropathological changes in
patients undergoing vigabatrin therapy (abstract). 18th
International Epilepsy Congress , New Delhi,
1989.
25.
Trottier S., Sazdovitch V.,
Chauvel
P. et al: Neuropathological study of brain
tissue in six patients treated with long-term vigabatrin (abstract).
18th International Epilepsy Congress, New
Delhi, 1989.
26.
Hauw JJ, Trottier S.,
Boutry
JM, et al: The neuropathology of
vigabatrin. Br J Clin
Pract1988;42(Suppl
61):10S-13S.
27.
Agosti R., Yasargil G.,
Egli
M., et al: Neuropathology of a human
hippocampus following long-term treatment with vigabatrin: Lack of
microvacuoles. Epilepsy
Res1990;6:166-170.
Cannon DJ, Butler WH,
Mumford
JP, Lewis PJ: Neuropathologic
findings in patients receiving long-term vigabatrin therapy for chronic intractable
epilepsy. J Child
Neurol1991;6
(Suppl):2S17-2S24.
30.
Arrezo JC, Schaumburg H.,
Spencer
PS: Structure and function of the somatosensory
system: A neurotoxicological perspective , in Hayes A (ed):
Toxicology of the Eye, Ear and Other Special Senses. New
York, Raven Press, 1985,
pp 41-45.
31.
Yiannikas C. , Walsh JC:
The use of visual evoked potentials in the detection of subclinical optic
toxicity secondary to ethambutol. Arch
Neurol1983;40:645-648.
Cosi V., Callieco R.,
Galimberti
CA, et al: Effects of vigabatrin on evoked
potentials in epileptic patients . Br J Clin
Pharmacol1989;27(Suppl
1):61S-68S.
34.
Liegeois-Chauvel C., Marquis P.,
Gisselbrecht
D., et al: Effects of long-term vigabatrin
on somatosensory-evoked potentials in epileptic patients.
Epilepsia1989;30(Suppl
3):23-25.
35.
Arezzo JC, Schroeder CE,
Litwak
MS, Steward DL: Effects of
vigabatrin on evoked potentials in dogs. Br J Clin
Pharmacol1989;27(Suppl
1):53-60.
36.
Persson LI, Rönnbäck L.,
Ben-Menachem
E., et al: Changes in CSF and brain soluble
protein following vigabatrin treatment in rats. Br J Clin
Pharmacol1989 ;27(Suppl
1):73-77.
Ben-Menachem E.:
Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids
in humans.
Epilepsia1989;30(Suppl
3):12-14.
39.
Riekkinen PJ , Ylinen A.,
Halonen
T., et al: Cerebrospinal fluid GABA and
seizure control with vigabatrin. Br J Clin
Pharmacol1989;27(Suppl
1):87-94.
40.
Ben-Menachem E., Persson LI,
Schechter
PJ, et al: The effect of different
vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic
patients . Br J Clin
Pharmacol1989;27(Suppl
1):79-85.
41.
Richens A.: The risks and
benefits of current and new anti-epileptic drugs. Br J Clin
Pract1988;42(Suppl
61):4-6.
42.
Ben-Menachem E., Persson LI,
Mumford
J., et al: Effect of long-term vigabatrin
therapy on selected neurotransmitter concentrations in cerebrospinal
fluid. J Child
Neurol1991;6(Suppl):2S11-2S16.
43.
Michelucci R., Tassinari CA :
Response to vigabatrin in relation to seizure type.
Br J Clin Pharmacol1989;27(Suppl
1):119-124.
44.
Livingston JH, Beaumont D.,
Arzimanoglou
A., Aicardi J.: Vigabatrin in
the treatment of epilepsy in children. Br J Clin
Pharmacol1989;27(Suppl
1):109-112.
45.
Chiron C., Dulac O.,
Luna
D., et al: Vigabatrin in infantile
spasms.
Lancet1990;335:363-364.
46.
Chiron C., Dulac O.,
Beaumont
D., et al: Therapeutic trial of vigabatrin
in refractory infantile spasms . J Child
Neurol1991;6(Suppl):2552-2559.
